Alnylam Pharmaceuticals' Amvuttra, used for hereditary ATTR amyloidosis and a newly approved cardiovascular indication, reported second-quarter revenues reaching $492 million, over double prior year sales. This strong uptake prompted an upward revision of full-year revenue guidance. Despite competition from BridgeBio and Pfizer, Amvuttra has exceeded Wall Street expectations, reflecting robust market penetration and positive clinical reception. The company forecasts continued growth, capitalizing on label expansion and demanding markets for rare disease therapies.